Nivolumab 3mg/kg, every 2 weeks

2 trials

Sponsors

Kobe city medical center general hospital

Conditions

Advanced NSCLC patients with IIPsnon-small cell lung cancer interstitial lung disease interstitial pneumonia

Unknown Phase

The pilot study of nivolumab for advanced NSCLC patients with IIPs which is clinically considered to be at low risk of acute exacerbation of IIPs.

Active, not recruitingJPRN-UMIN000022037

Kobe city medical center general hospitalAdvanced NSCLC patients with IIPs

Start: 2016-04-19Target: 6Updated: 2026-06-29

The prospective study of nivolumab for advanced NSCLC patients with mild IIPs

Active, not recruitingJPRN-UMIN000026129

Kobe city medical center general hospitalnon-small cell lung cancer interstitial lung disease interstitial pneumonia

Start: 2017-02-14Target: 18Updated: 2026-06-29

Related Papers

A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.

2017-06-1761 citations